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Abstract
The phylogenetically conserved family of Muscleblind proteins are RNA-binding factors involved in a variety of gene
expression processes including alternative splicing regulation, RNA stability and subcellular localization, and miRNA
biogenesis, which typically contribute to cell-type specific differentiation. In humans, sequestration of Muscleblind-like
proteins MBNL1 and MBNL2 has been implicated in degenerative disorders, particularly expansion diseases such as
myotonic dystrophy type 1 and 2. Drosophila muscleblind was previously shown to be expressed in embryonic somatic and
visceral muscle subtypes, and in the central nervous system, and to depend on Mef2 for transcriptional activation. Genomic
approaches have pointed out candidate gene promoters and tissue-specific enhancers, but experimental confirmation of
their regulatory roles was lacking. In our study, luciferase reporter assays in S2 cells confirmed that regions P1 (515 bp) and
P2 (573 bp), involving the beginning of exon 1 and exon 2, respectively, were able to initiate RNA transcription. Similarly,
transgenic Drosophila embryos carrying enhancer reporter constructs supported the existence of two regulatory regions
which control embryonic expression of muscleblind in the central nerve cord (NE, neural enhancer; 830 bp) and somatic
(skeletal) musculature (ME, muscle enhancer; 3.3 kb). Both NE and ME were able to boost expression from the Hsp70
heterologous promoter. In S2 cell assays most of the ME enhancer activation could be further narrowed down to a 1200 bp
subregion (ME.3), which contains predicted binding sites for the Mef2 transcription factor. The present study constitutes the
first characterization of muscleblind enhancers and will contribute to a deeper understanding of the transcriptional
regulation of the gene.
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Introduction
Muscleblind proteins were initially identified in Drosophila and
associated to the development of the embryonic peripheral
nervous system [1], the muscles [2] and the adult photoreceptors
[3]. They were later found to regulate alternative splicing of
defined pre-mRNAs by binding to specific consensus sequences
and to hairpins containing pyrimidine mismatches through
conserved zinc finger motifs of the CCCH type ([4,5] and
reviewed in [6]). Muscleblind target transcripts encode cell
adhesion and cytoskeleton components, proteins involved in
muscle excitation and contraction, structural proteins in muscle
sarcomere and signalling molecules, among others [5,7,8,9,10,11].
Through alternative splicing musclebIind transcripts themselves
generate at least fourteen transcript isoforms. Most of them share
common 59 sequences but differ at the 39-ends, encoding proteins
of different lengths and carboxyl termini. The muscleblind
transcriptional unit is large and has a complex organization with
ten exons distributed over about thirty times more than the
average gene length in Drosophila [5,12].
In contrast to Drosophila, which has a single gene, three
Muscleblind-like homologs (MBNL1, MBNL2, and MBNL3) exist
in humans and mice [13,14]. Although recent results have
highlighted MBNL proteins as regulators of messenger RNA
(mRNA) stability [15,16,17], localization [10,18] or miRNA
biogenesis [19] in the cytoplasm, these proteins are particularly
well-known for their nuclear function as alternative splicing
regulators. MBNL1 plays a primary role in alternative splicing
allowing the fetal-to-adult splicing transitions needed for develop-
ment of skeletal and cardiac muscle whereas MBNL2 seems to
perform a similar function in the central nervous system [20,21].
Similarly, MBNL1 and MBNL2 are direct negative regulators of a
large program of cassette exon alternative splicing events that are
differentially regulated between embryonic stem cells and other
cell types [22]. In contrast, MBNL3 has been reported as a
member of the family with unusual functions. MBNL3 antagonizes
muscle differentiation by promoting exclusion of the alternatively
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spliced b-exon of Myocyte enhancer factor 2D (Mef2D) [23] and also by
the inhibition of myogenesis by maintaining myoblasts in a
proliferative state [24,25]. As a result of this regulation a negative
correlation exists between MBNL1 and MBNL3 expression levels
in muscle during development when MBNL3 is mainly detected
during embryonic development, but also transiently during injury-
induced adult skeletal muscle regeneration [13,26]. MBNL1 and
MBNL2 have a similar expression pattern in skeletal and heart
muscle, kidney, liver, lung, intestine, brain and placenta. However,
MBNL1 expression in skeletal muscle is higher than MBNL2
[13,25].
Drosophila Muscleblind shows tissue-specific expression during
development. In eye-antennal imaginal discs Muscleblind is
required for the formation of photoreceptor rhabdomeres,
identifying muscleblind as a general factor required for terminal
differentiation of adult ommatidia [3]. Its expression was also
reported in the embryonic central nervous system and in the
somatic muscles, where disruption of muscleblind caused defects on
muscle attachments to the epidermis and disrupted Z-band
formation in muscle sarcomeres [2]. Recent studies have revealed
a role for muscleblind in the myoblast fusion process through a
splice-independent regulation of muscle protein 20 (Mp20), a gene
that promotes myoblast fusion [11]. Consistent with its function
during terminal muscle differentiation, Drosophila Myocyte en-
hancer factor 2 (Mef2) activates muscleblind in embryos, placing this
gene downstream of Mef2 function in the myogenic differentiation
program in flies [2]. The muscleblind chaste mutation has revealed
that the gene is not only required during embryo development but
also in adult brain, where it is necessary for the normal
development of neural circuitry that regulate female sexual
receptivity [27].
Muscleblind-like proteins are critically involved in many
pathogenesis pathways, but most notably in myotonic dystrophies
type 1 and type 2 (DM1 and DM2; reviewed in [6,28]). DM1 is
caused by the expansion of the unstable CTG triplet in the
39untranslated region of the Dystrophia Myotonica Protein Kinase
(DMPK) gene [29]. DM2 patients carry an unstable CCTG repeat
expansion in intron 1 of CCCH-type zinc finger nucleic acid binding
protein (CNBP) [30]. In both cases, transcribed repeat expansions
form ribonuclear foci that have the ability to sequester, among
others, MBNL proteins, which are therefore depleted from their
normal functions [14,31,32]. DM1 and DM2 are typically
regarded as muscular diseases but many other organs are also
affected resulting in eye cataracts, cognitive dysfunction and
cardiac conduction defects.
Despite biomedical and developmental relevance, the knowl-
edge on the transcriptional regulation of muscleblind genes,
particularly in Drosophila and in humans, is extremely limited.
With the aim to fill this gap, in this study we have performed in
silico and in vivo analyses to define gene promoters and tissue-
specific cis-regulatory regions that control Drosophila muscleblind
expression. Using a candidate approach, we have identified two
putative gene promoters, located in exon 1 and exon 2, and have
confirmed two intronic regions with the ability to drive expression
to embryonic somatic muscle and the nerve cord. This constitutes
the first description of tissue-specific enhancers and provides new
insights into the muscleblind gene.
Results
1. Mapping of the Promoter Regions of Drosophila
muscleblind
The analysis of available cDNA sequences and expressed
sequence tags (EST) involving the muscleblind locus showed that 59-
end sequences clustered to two locations in the gene, to the
beginning of exon 1 and to the beginning of exon 2 (Fig. 1B),
which suggests that muscleblind might have two transcription start
sites (TSS). To test this hypothesis we defined two regions as
potential promoters of muscleblind. P1 ranged from 2180 to +335
(515 bp long) while P2 spanned from 2243 to +343 (586 bp long)
(Fig. 1A), defining as +1 the first bp in exon 1 and exon 2,
respectively. Although core promoter regions are typically defined
as +50 to 250 of transcription start site [33], a longer region was
used to include not only the core promoter but also proximal
promoter sequences with potential activator binding sites.
A SCOPE database analysis of Drosophila promoter elements
[34] confirmed the accumulation of known consensus sequences in
P1 and P2, thus supporting their potential as promoter regions
(Fig. 1 C,D). Furthermore, these motifs were phylogenetically
conserved among Drosophila species in the Multiz Alignments &
phastCons Scores provided by the UCSC, supporting the
relevance of these non-coding regions (data not shown). To test
the functional relevance of the putative promoters we generated
reporter constructs in which P1 and P2 drove expression of Firefly
luciferase. In addition, we also tested the activity of shorter
versions, contained in the longer ones, of 220 bp long (2104 to +
116; P1.1) and 397 bp long (281 to +316; P2.1), respectively, in an
attempt to define minimal promoters. Dual luciferase reporter
assays in Drosophila S2 cells transfected with the resulting constructs
revealed that P1 was able to boost luciferase readings more than
100 fold higher relative to the promoter-less control. This was 2.5
fold the transcription measured for P1.1, 12 fold higher than the
luciferase activity driven by P2 and 7 times the activity measured
for P2.1 (Fig. 1E). Thus, robust expression of luciferase was
observed in P1 constructs in comparison to reporter expression
driven by P2, and the higher activity obtained with P1 in
comparison to P1.1 suggests that P1 contains proximal promoter
elements that are not included in P1.1.
2. Identification of Putative cis-regulatory Modules
Potential cis-regulatory elements of transcription can be
identified as highly conserved non-coding regions in phylogenetic
footprinting analyses (as an example see [35]). A fragment of
120 kb harbouring most of the muscleblind gene, plus 20 kb
upstream of the gene (complete sequence analyzed chr2R:
13133058–13252891), was used as the reference DNA to align
orthologous sequences from 12 Drosophilids. Using the bioinfor-
matics tool rVista, an intronic sequence showing above 90%
identity in a 100 bp window between Drosophila melanogaster and
D.mojavensis was selected. This sequence, refered to as H region,
was 872 bp long and was located in intron 2 (Fig. 2A and Table 1).
Moreover, chromatin immunoprecipitation followed by micro-
array analysis (ChIP-on-chip) data revealed putative cis-regulatory
modules (CRMs) M1, M2, M3 and ML (Fig. 2A and Table 1) in
the muscleblind locus that bound Drosophila Mef2 [36,37,38]. We
found these results particularly relevant because Mef2 is a known
activator of muscleblind expression in the Drosophila embryo [2].
Interestingly, these candidate CRMs not only bind Mef2 in ChIP-
on-chip experiments but also other muscle organizing factors such
as Biniou (Bin), Tinman (Tin) or Twist (Table 1). The ML region
only bound Mef2 in late embryos according to [37].
3. In vivo Testing of Reporter Expression Reveals Tissue-
specific Enhancers
To test the regulatory potential of the highly conserved (H) and
the Mef2-bound (M1, M2, M3 and ML) genomic regions
involving the muscleblind locus, we generated fusion constructs in
the Drosophila transformation vector pH-Stinger. This vector
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contains the heat shock protein 70 (Hsp70) promoter and is specifically
designed to avoid chromatin configuration effects (‘‘position
effects’’) by flanking the eGFP reporter cDNA with two copies
of insulator sequences from the gypsy transposon [39]. Embryonic
expression of the eGFP was assessed either directly (green
fluorescence) (Fig. 2) or immunodetecting the reporter protein
with a polyclonal anti-GFP antibody (Fig. 3). Only embryos
carrying reporter constructs under the control of the M2 and ML
candidate CRMs revealed consistent patterns (Fig. 2G–I; Fig. 3;
and not shown) and in both cases eGFP expression was restricted
to nuclei, as expected by the presence of a nuclear localization
signal in the vector.
We have previously shown that Muscleblind is localized in the
nuclei of embryonic pharyngeal, visceral and somatic muscles, in
the larval photoreceptor system, and in repeated clusters of cells
within the central nervous system [2,3] (Fig. 2B,C). In combination
with the Hsp70 promoter, M2 drove robust eGFP expression in the
somatic musculature of late embryos, approximately starting from
stage 13. Notably, no eGFP expression was detected in other
muscle derivatives or tissues where endogenous muscleblind is
normally detected, particularly the CNS (Fig. 2I). As control, we
generated transgenics carrying a promoter-less M2:eGFP con-
struct, which revealed no eGFP expression (Fig. 2D–F), thus
confirming that M2 had no promoter activity by itself but requires
the presence of a promoter to exert its enhancer activity. Similarly,
Figure 1. Organization of the muscleblind genomic region. (A) Representation of 90 kb of the Drosophila melanogaster muscleblind gene.
Green boxes represent exons and black lines introns. Representation according to [5]. Candidate promoter regions P1 and P2, and their shorter
versions P1.1 and P2.1, are indicated. Black arrows denote putative transcription start sites located in exons 1 and 2. (B) 59-Ends of ESTs mapping to
the muscleblind gene, according to the UCSC Genome Browser, suggest that most transcripts start in exon 1 and 2. Genomic context around exon 1
(C) and exon 2 (D). Exonic sequence is in capital letters, P1 and P2 are highlighted in blue (GenBank accession numbers KJ398152 and KJ398154,
respectively), and P1.1 and P2.1 are underlined (GenBank accession numbers KJ398151 and KJ398153, respectively). Blue boxes denote promoter
consensus sequences with Sig value greater than 7 according to Scope (significant by default). (E) Relative luciferase activity from transiently
transfected Drosophila S2 cells. Luciferase activity was stronger from P1 (or P1.1) than from P2 (or P2.1) promoters. Luciferase activity was measured
48 h after transfection. Renilla expression levels were used to normalize cell number, transfection efficiency, and general effects on gene
transcription. All data were also normalized to luciferase levels of the empty vector pGL3 Basic. ***P,0.001. Bar graph shows means+s.e.m. from
three independent experiments with three technical replicates each.
doi:10.1371/journal.pone.0093125.g001
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double eGFP and Muscleblind immunostaining of fly embryos
carrying ML:eGFP constructs revealed that ML drove expression
to clusters of cells in the ventral cord of late embryos that
overlapped with those expressing endogenous Muscleblind (Fig. 3).
First signal started at developmental stage 12 and no eGFP
expression was detected in tissues other than the CNS. Consis-
tently, ML included predicted binding sites for factors involved in
nervous system development such as Ladybird early (Lbe),
Ladybird late (Lbl), Kru¨ppel (Kr) and Hunchback (Hb)
[40,41,42,43] (Fig. 4G). In summary, these results support that
M2 and ML are somatic muscle and CNS-specific enhancers of
muscleblind, respectively, at least during embryonic development.
Figure 2. ME reproduces muscleblind expression in the embryonic somatic musculature. (A) Localization of the putative cis-regulatory
modules M1, M2, ML, H and M3, indicated as orange boxes, in the context of the muscleblind genomic locus. Fluorescence confocal images of lateral
(B,E,H,) and ventral (C,F,I,) views of late Drosophila embryos. (D,G) Schematic representation of the reporter constructs used to transform the germline
of Drosophila. In control yw flies (B,C) an anti-Mbl antibody detects robust expression in the somatic musculature and in the CNS (green). Direct
visualization of the GFP reporter under the control of the ME enhancer in the pH-Stinger vector (E,F,H,I). Promoter-less ME constructs (D–F) do not
activate GFP expression and serve as negative controls. Flies carrying the ME enhancer upstream of Hsp70 (G–I) reproduce Muscleblind expression in
the somatic musculature but not in the CNS. All micrographs were taken at 2006magnification. Anterior is to the left and dorsal up unless otherwise
stated.
doi:10.1371/journal.pone.0093125.g002
Table 1. Putative cis-regulatory modules (CRMs) chosen for in vivo testing of reporter expression.
CRM Location Size (bp) TF binding sites
M1 Upstream 2278 1 Twi
6 Mef2
1 Bin
M2 Intron 2 3340 2 Mef2
3 Bin
M3 Exon 4 1240 3 Mef2
1 Bin
ML Intron 2 830 3 Mef2
1 Bin
H Intron 2 872 0
All except region H according to [37].
doi:10.1371/journal.pone.0093125.t001
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We therefore renamed these candidate CRMs as ‘‘ME’’ (from
muscle enhancer) and ‘‘NE’’ (from nervous system enhancer).
Importantly, both ME and NE were capable of activating a
heterologous promoter, a typical ability of transcriptional enhanc-
er elements.
4. Characterization of the Muscle and Nervous Enhancer
Elements of muscleblind
To test the ability of ME and NE genomic regions to enhance
transcription from the putative muscleblind promoters, we used
luciferase reporter assays in Drosophila S2 cells. We used S2 cells
because this is a well characterized cell line whereas muscle or
neuron-specific cell lines were not immediately available. Both
enhancer regions were cloned upstream to each of the putative
promoters P1, P1.1, P2 and P2.1 in their forward (Fig. 4A) and
reverse (not shown) orientations in the pGL3 basic vector, which
carries the Firefly luciferase reporter. As controls, ME and NE
were tested in promoter-less constructs and no luciferase activity
was detected (data not shown), thus confirming that the enhancer
regions do not have any transcriptional activity by themselves.
When promoters were in the forward orientation we observed that
the transcription originated from P1 and P1.1 was strongly
enhanced by ME, whereas NE had no effect on P1.1, or even
decreased transcription when in combination with P1 (Fig. 4B).
Similarly, P2 and P2.1 promoter activity was significantly
enhanced by NE (around 30% and 20%, respectively), but
remained unchanged when in combination with ME that even
repressed transcription from P2.1 (Fig. 4C). As control of promoter
directionality, luciferase levels of constructs carrying promoters in
their reverse orientation were measured. Consistently, relative
luciferase readings dropped to close to background levels in
constructs containing promoters in their reverse orientation (Fig. 4
compare B,C with D), although both ME and NE still managed to
significantly potentiate transcription from P1 and P1.1. Thus,
promoter activity is orientation-dependent, as reversed promoters
expressed significantly less luciferase reporter, and the activity of
the ME and NE enhancers on P1 and P2 suggests enhancer-
promoter communication specificity.
ME function was further analyzed to narrow down sequences
necessary for enhancer activity. This involved testing three smaller
regions, approximately 1 kb each, here referred to as ME.1, ME.2
and ME.3 according to their relative position in the original region
(Fig. 4A). These sequences were cloned upstream to the P1 and
P1.1 promoters and were used in luciferase reporter assays in S2
cells (Fig. 4E). Compared to the luciferase activity of the promoter
alone, ME.3 was the only subregion able to significantly increase
transcription from P1.1, also showing the same trend on the P1
promoter. Notably, all other subregions tested either did not boost
expression from P1 or P1.1 or even inhibited it. Therefore, these
data, and bioinformatics analyses support that ME.3 contains
sequence motifs necessary for ME enhancing activity, including
consensus Mef2 binding sites (Fig. 4F), but they also suggest that
for maximum enhancing activity all three subregions are required.
Bioinformatics analyses in NE found an enrichment of targets for
nervous system transcription factors (Fig. 4G).
5. Functional Conservation of Human MBNL1 Promoter
Sequence conservation between Drosophila and human MBNL1
promoter sequences was patently non-existent. However, analysis
of available cDNA sequences and ESTs in the MBNL1 locus
suggested that human MBNL1 might also use TSS located in exon
1 and in exon 2 (Fig. 5A). Consistently, putative TSS includes
Figure 3. NE reproducesmuscleblind expression in the central nervous system. (A) Schematic representation of the reporter construct used
to transform the Drosophila germline. Fluorescence confocal images of lateral (B–D) and ventral (E–J) views of late Drosophila embryos expressing
construct (A) co-stained with anti-GFP (green) and anti-Mbl antibodies (red). NE drives expression in the CNS (arrows; C,I) overlapping Muscleblind
expression (B,E,H; D,G,J shows the merge in yellow). No signal of the reporter was observed in tissues other than CNS. Endogenous Muscleblind
expression in the muscles is in focus in (E,G,H,J). Micrographs were taken at 2006 (B–G) and 4006magnification (H–J). Anterior is to the left and
dorsal up unless otherwise stated.
doi:10.1371/journal.pone.0093125.g003
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promoter marks such as CpG islands and histone modification
tracks (Fig. 5A,B). We defined 500 bp around the predicted start
region from both exons to test them as putative human MBNL1
promoters; Hsa-P1 in exon 1 (chr3: 151985544–151985045) and
Hsa-P2 in exon 2 (chr3: 152016823–152017382). Synthetic Hsa-
P1 and Hsa-P2 sequences were designed to replace the Hsp70
promoter in the Drosophila transformation pH-Stinger vector. No
eGFP expression was observed in transgenic fly embryos carrying
any of the human promoters alone (data not shown and Fig. 5D–
F). However, we observed a robust expression of eGFP in the
somatic musculature of embryos when ME drove expression of the
Hsa-P1 promoter (Fig. 5G–I compare to Fig. 2B,C). This
expression was not observed in similar reporter constructs where
Hsa-P2 replaced Hsa-P1 (ME-Hsa-P2; not shown). These data
support that Hsa-P1 can initiate transcription, as we have also
demonstrated for the muscleblind P1 promoter, and that ME is a
muscle enhancer on a variety of promoters.
Figure 4. ME and NE boost P1 and P2 promoter activity, respectively. (A) Schematic representation of the Firefly luciferase reporter
constructs used to transiently transfect Drosophila S2 cells. (B) ME, but not NE, potentiates P1 or P1.1 promoter activity. Basal promoter activity of P1
is significantly higher than P1.1 in these assays. Conversely, NE, but not ME, weakly enhanced P2 or P2.1 promoter function (C), being the relative
luciferase activity measured approximately one tenth of that from P1 or P1.1. (D) Reversed P1 and P1.1 promoters still responded to ME and NE,
although at much lower levels, whereas P2 and P2.1 did not significantly change reporter expression. (E) ME (GenBank accession number KJ201027)
was subdivided into three smaller regions of approximately 1 kb (ME.1, ME.2 and ME.3). ME.3 retained most of ME ability to boost expression,
although only for P1.1 it reached statistical significance. ME.3 and NE (GenBank accession number KJ201028) sequences are enriched in consensus
binding sites for Mef2 (underlined) (F) and nervous system (G) transcription factors according to the following code: Hunchback sites, underlined;
Ladybird early and Ladybird late, bold; Kru¨ppel, italics respectively. Predictions used the Jaspar and rVista programs.
doi:10.1371/journal.pone.0093125.g004
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Discussion
Muscleblind orthologues have attracted intense research interest
due to their important role in vertebrate muscle development as
well as involvement in several degenerative RNA-mediated
diseases including DM1 and DM2, Huntingtons disease, Hun-
tington’s disease-like (HDL2) or spinocerebellar ataxia 8 (SCA8)
[6,44,45,46]. More recently, MBNL proteins were found to
repress embryonic stem cell alternative splicing patterns, uncov-
ering an additional role in the control of the cell pluripotency [22].
Despite this, little is known about the transcriptional regulation of
muscleblind genes both in Drosophila and in vertebrates.
As a means of dissecting the cis-regulation of muscleblind, we
analyzed a genomic DNA fragment harboring the muscleblind locus
and its upstream region, looking for CRMs that regulate basal
initiation of transcription (promoters) and tissue-specific expression
(enhancers). In silico and in vivo studies identified two putative
promoters, P1 in exon 1 and P2 in exon 2, and two intronic tissue-
specific regulatory elements, a region of 3340 bp which drives
specific expression in somatic muscle (ME) and a region of 830 bp
which drives expression in central nervous system (NE). Both
enhancers had been selected because of their enrichment in Mef2
binding sites according to ChIP-on-chip data [37], because Mef2
is a known positive regulator of muscleblind in the embryo [2].
Nevertheless, other enhancer elements must exist in order to
explain the rich embryonic expression pattern of muscleblind, which
also includes expression in visceral and pharyngeal musculature,
the Bolwigs organ (the larval photoreceptor system) and the
imaginal discs [2,3]. Regarding this, putative CRMs that did not
reproduce any embryonic pattern in our study can not be
discarded as functional in other developmental stages.
Enhancer regions ME and NE were able to boost expression
originating from the heterologous Hsp70 promoter in transgenic
Figure 5. Genomic organization of the human MBNL1 gene. (A) Scale representation of 198 kb of the human MBNL1 locus. Green boxes
correspond to exons and black lines to introns. Tested promoter regions are indicated as P1 and P2; a yellow circle denotes a predicted CpG island. (B)
Schematic representation of H3K27Ac marks, typical of promoter regions, on seven human cell lines. (C) 59-Ends of ESTs mapping to the MBNL1 locus
support two potential transcription start sites for the gene. Data according to the UCSC Genome Browser [58]. (E,F,H,I) Direct visualization of the eGFP
reporter under the control of the ME enhancer. (D–F) Enhancer-less Hsa-P1 construct is a negative control. (G–I) Flies carrying the ME enhancer
upstream of the human MBNL1 promoter (Hsa-P1) reproduce Muscleblind expression in the somatic musculature. (E,H) Lateral and (F,I) ventral views
of late embryos. All micrographs were taken at 2006magnification. Anterior is to the left and dorsal up, unless otherwise stated.
doi:10.1371/journal.pone.0093125.g005
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embryos. However, in luciferase S2 assays, ME preferentially
activated the P1 promoter while NE showed preference for P2,
although the enhancer activity of NE was smaller than that of ME
and transcription arising from P2 was on average one tenth of that
from P1 (Fig. 4B,C). Our results in transgenic flies carrying the ME
in combination with the human MBNL1 P1 promoter also suggest
enhancer promoter specificity as ME only induced reporter
expression from Hsa-P1, but not from Hsa-P2. The use of
alternative promoters is a known mechanism of transcriptional
regulation, which has been reported to influence levels of
transcription, turnover or translation efficiency of mRNA isoforms
with different leader exons, tissue specificity [47] and to generate
protein isoforms differing in the amino termini (reviewed in [48]).
Furthermore, different core promoters have been found to possess
distinct regulatory activities driven by the same enhancer in the
Drosophila embryo ([49]). In muscleblind, the potential in vivo use of
P1 and P2 as alternative promoters would have no consequences
as for the encoded protein since the start codon is located in exon
2, which is downstream of both. However, the in vivo relevance of
the internal promoter P2 remains to be specifically addressed. It is
also worth mentioning that whereas the identified enhancers
provided strong activation of the reporter in vivo, particularly ME,
the measured activation in S2 cells was discrete, reaching some 6-
fold increase over the promoter alone condition (Fig. 4B). This
may stem from the particular combination of transcription factors
that S2 cells express, which may not be particularly favourable to
activate myogenic enhancers. Mef2, for example, is weakly
expressed in S2 cells according to modENCODE data [50],
and, consistently, Muscleblind is only barely detectable in this cell
line [51]. Nevertheless, the low expression of Muscleblind in S2
cells offers an opportunity to test the activating potential of
candidate regulatory transcription factors.
Despite that sequences homologous to ME or NE in human
MBNL1 are not obvious, ENCODE Chip-seq data confirms that
there is a high concentration of transcription factor binding sites in
the first intron of MBNL1, including multiple MEF2A and
MEF2C binding regions, thus suggesting that MEF2, a central
regulator of diverse developmental programs [52], is also involved
in the regulation of human MBNL1 transcription. Indeed, detailed
information on the multiple transcription factors converging on
the Drosophila ME and NE enhancer elements would help in the
identification of the functionally equivalent enhancer regions that
integrate inputs from the same factors in humans. Although
hypothetical, the functional conservation among fly and human
muscleblind enhancers is conceivable. Deformed enhancers, for
example, drive meaningful spatial expression patterns in vivo in a
mouse context [53]. In any event, this initial characterization of
cis-regulatory regions is the first step towards the understanding of
the transcriptional regulation of muscleblind.
Materials and Methods
Constructs
P1 and P2, and their shorter versions P1.1 and P2.1, promoter
regions were synthesized by GenScript with NheI/XhoI terminal
adapters and were provided cloned into the pUC57 vector. High
fidelity PCR (KAPA HiFi DNA Polymerase, KAPA biosytems)
was used to subclone into the pGL3-Basic vector (Promega)
previously linearized with the same enzymes. ME, ME.1, ME.2,
ME.3 (spanning from 13170622–13171543, ME.1; 13171544–
13172759, ME.2; 13172760–13173908, ME.3) and NE were
obtained from Drosophila genomic DNA by high fidelity PCR and
were cloned into KpnI/SacI digested pGL3-Basic vectors already
including different promoter regions. To generate transgenic flies,
M1, M2, M3, H and ML fragments were PCR amplified from
genomic DNA and were cloned into the BglII and XbaI sites of the
Drosophila expression vector pH-Stinger [54]. Synthetic Hsa-P1
and Hsa-P2 promoter regions, including PstI, BglII, XhoI (59) and
HindIII, PstI (39) adapter sites, were cloned into the pUC57 vector
and subsequently transferred to the PstI site of the pH-Stinger
vector. To generate ME-Hsa-P1 and ME-Hsa-P2 constructs, M2
was amplified with specific oligos containing BglII/XhoI adapters,
digested, and cloned into the corresponding sites of the pH-Stinger
vector already containing the candidate human promoters. All
constructs were confirmed by sequencing. Description of used
primers is in Table 2.
Cell Culture and Dual Luciferase Assays
Drosophila melanogaster Schneider 2 cells (S2) were cultured at
27uC in growing media containing 90% Schneiders insect media
(Gibco), 10% heat inactivated fetal bovine serum (FBS), 100 units/
ml of penicillin and 100 mg/ml of streptomycin. 48 h before
transfection, 106 log-phase cells were transferred onto 24-well
plates (300 ml per well). 4 ml of Cellfectin reagent (Invitrogen) in
200 ml of serum and antibiotic-free medium were used to co-
transfect 450 ng of the pGL3 reporter plasmid of interest and
25 ng of Renilla luciferase. A GFP expressing vector served as
transfection efficiency control. Cells were incubated 16 h with
transfection mix, then media was replaced by Schneiders complete
medium and the culture was additionally maintained 24 h at
27uC. Luciferase expression was monitorized using the Dual-
Luciferase Reporter Assay System (Promega). Briefly, this involved
adding 100 ml of lysis buffer per well, shaking for 15 min and
transferring the lysate to a white 96-well plate with 40 ml of
luciferase substrate. After 10 s of luminescence detection,
Stop&Glo buffer was added and luminescence measurement was
repeated. Luminescence readings used an EnVision plate reader
(PerkinElmer). In cell culture luciferase reporter assays, all graphs
show the average of three independent experiments with three
technical replicates each. P-values were obtained using a two-
tailed, non-paired t-test (a=0.05). Welch’s correction was applied
when variances were significantly different.
Immunohistochemistry of Drosophila Embryos
Embryos were fixed for 20 min using 4% paraformaldehyde in
PBS, devitelinized with a heptane:methanol 1:1 mixture, and
blocked with 0.1% Triton-X-100 in PBS (PBT) with 1% BSA for
15 min and later with 2% BSA in PBT for 30 min. Subsequently
they were incubated with rabbit anti-GFP (1:200 Torrey Pines
Biolabs) antibody diluted in blocking solution containing 1%
donkey serum for 2 h at room temperature. After washes embryos
were incubated with an anti-rabbit-FITC (1:200 Calbiochem)
secondary antibody for 45 min. Muscleblind detection used sheep
anti-Muscleblind (1:500 [55]) for 2 h followed by washes and
primary antibody recognition with sheep biotin-conjugated
secondary antibody (1:100, Sigma) for 2 h. Then, washed embryos
were incubated with ABC solution (ABC kit, VECTASTAIN) for
30 min at room temperature, and were washed and incubated
with streptavidin-Texas Red (1:1000, Vector) for 45 min. In all
cases embryos were washed 36with 1% BSA in PBT and were
mounted in Vectashield (Vector) with 2 mg/ml DAPI. Images
were taken on an Olympus FluoView FV100 confocal microscope.
At least 10–15 embryos of the desired stage, and showing the
relevant expression patterns, were analyzed.
Drosophila Strains and Transgenics
Genomic DNA was extracted from the Drosophila genome
project strain y1; Gr22b1 Gr22d1 cn1 CG33964R4.2 bw1 sp1; LysC1
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MstProx1 GstD51 Rh61 (Bloomington Drosophila Stock Center,
Bloomington IN). y1w1118 flies were also from Bloomington IN.
All constructs were injected into w1118 embryos by BestGene,
typically resulting in 2–6 independent transgenic lines.
Web Resources
Predictions of transcription factor binding sites used JASPAR
[56]. Phylogenetic conservation employed the Whole Genome
rVISTA browser [57]. EST mapping was according to the UCSC
Genome Browser database [58]. Predicted promoter consensus
sequences used Suite for Computational Identification of Promot-
er Elements (SCOPE) [34]. Genomes of reference were Drosophila
BDGP R5/dm3 and human GRCh37releases.
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